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CC BY-NC-ND license (http://creativeAbstract Background: A common assumption with autonomic assessment is that one branch
opposes the other. With independent measures of parasympathetic (P) and sympathetic (S) ac-
tivity, based on concurrent time-frequency analysis of respiratory activity and heart rate vari-
ability, this assumption has been challenged. Clinical observations of unprovoked P-excess
during S-stimulation have been associated with treatable, abnormal responses.
Method: Serial autonomic profiling of 12,967 patients was performed using the P&S method
(ANX-3.0 Autonomic Monitor by ANSAR Medical Technologies, Inc., Philadelphia, PA) over a
five-year period. Treatment protocols are very low-dose and depend on patient history. For
cardiovascular disease patients, Carvedilol was prescribed. For non-CVD patients, Nortriptyline
was prescribed. In some cases where end-organ effects were not yet presented or relieved,
patients were weaned of therapy once PE was relieved. Alternative therapies included Specific
Chiropractic Adjustment, better known in the literature as Chiropractic Manipulative Therapy
and intensive zero-impact, cardiovascular exercise.
Results: PE patients present with normal HR and BP and no other apparent symptoms at rest.
However, they reported symptoms of: sleep difficulties, palpitations, poor peripheral circula-
tion, general malaise, depression (often with anxiety or ADD-like symptoms), frequent head-
ache or migraines, menopause difficulties in women, hypothyroidism, cognitive difficulties,86 10339889.
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SW sympathetic withdrawgastrointestinal upset, persistent weight-gain, and dizziness after standing.
Conclusion: Normalizing PE, regardless of method, stabilizes the patient, relieves symptoms,
improves quality of life, and improves patient outcomes.
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Clinical observations of unprovoked parasympathetic
excess (PE) are associated with abnormal clinical and
pathophysiologic responses. PE may occur with or without
abnormal sympathetic (S) activity. Chronic conditions such
as diabetes,1e5 thyroid disease,6 kidney disease,7 cardio-
vascular disease,11,12 demyelinating and inflammatory
neurological diseases,8 some dementia,9 depression, and
altered psychological states9 may cause autonomic imbal-
ance and associated P-dysfunction. Severe acute conditions
may precipitate PE, including trauma, injury, infection,
surgery, cancer, and myocardial infarction. Preliminary
evidence suggests that severe or chronic exposure to
chemicals, cold, and allergens may induce PE as well as
multiple pregnancies for women. Stress, excess caffeine,
nicotine, and other chemical10,11 and environmental expo-
sures affect autonomic balance. History assessment in-
dicates that genetically mediated, or congenital, PE may be
evidenced as colic in infants followed by intermittent (be-
tween developmental cycles during the childhood and
teenage years) sleep difficulties, or depression with anxi-
ety, or ADD. PE is associated with difficult to manage pa-
tients including those with difficult to control blood
pressure (BP), blood glucose, and hormone levels (i.e.,
thyroid, estrogen, or growth hormones), and persistent
weight-gain.
Establishing PE may help clarify a diagnosis when pa-
tients present with multiple, confounding or conflicting
symptoms (e.g., hypertension with depression, depressionwith anxiety, hypotension with nighttime sleeplessness,
and CRPS) and provide a more integrated approach to
therapy. Disease may cause P&S imbalance, for example
pain causes S-excess (SE) which may lead to early hyper-
tension. Symptoms appearing as disease may be caused by
P&S imbalances, such as when dizziness upon standing
(orthostasis or syncope) is caused by PE with secondary S-
dysfunction. Therefore, it seems reasonable to hypothesize
that P&S imbalances such as PE or SE are separate and
distinct dysfunctions. A single agent, however, may often
address both the primary disease and the P or S disorder,
and PE may be treated directly. Once PE is relieved, often
the patient is more stable and the primary disease(s) may
be treated more aggressively.
Often PE is not detected at rest, and therefore not
detected with the standard office physical. Furthermore, it
is often associated with (secondary) SE and associated with
symptoms (high BP, palpitations, anxiety). Remember, P-
activity established the threshold around which S-activity
responds. As a result, SE is treated and often the patients
are (seemingly) unresponsive or become worse. Clinical
evidence has shown that detecting, and thereby treating,
PE will lead to normalized SE which will lead to relief of
both SE-related symptoms and PE-related symptoms.
P&S Monitoring has documented failures in the reactive
pushepull dynamics within the ANS.12e15 Measures based
solely on Heart Rate Variability (HRV) or beat-to-beat BP
often fail to isolate P- from S-activity.13e15,20,21 Indepen-
dent, simultaneous P&S measures are critical to under-
standing the true nature of autonomic dysfunction and its
clinical implications.16e21 Documentation of P&S activity
has provided more insight into many commonly observed
clinical conditions. PE is often the primary autonomic dis-
order and S-abnormalities appear to be secondary.Methods
Serial P&S profiling of 12 967 patients (7424 females,
57.25%) was performed (ANX-3.0 Autonomic Monitor by
ANSAR Medical Technologies, Inc., Philadelphia, PA). Pa-
tients ranged in age from 6 to 100 years. Patients with high
quality ectopy were omitted from this analysis. Data were
collected over a five-year period at 19 primary care and
ambulatory clinics. Patients were followed for at least 18
months as a matter of routine, based on their primary
diagnosis. EKG and respiratory data were collected
concurrently, and analyzed to compute independent,
simultaneous P&S activity measures (the P&S Method).20,21
P&S assessment was based on a clinical study that included
(in order): 1) five-minute of rest (initial baseline); 2) one
54 D.L. Bellin et al.minute of relaxed paced breathing at six breaths per min-
ute; 3) one minute of rest to return to baseline; 4) a series
of five, short Valsalva maneuvers in a period of one minute
and 35 seconds; 5) two minutes of rest; and 6) a quick head-
up postural change followed by 5 minutes of quiet head-up
posture (standing).
Treatment protocols were very low-dose and depend on
patient history. For cardiovascular disease patients under
65 years of age, 3.125 mg Carvedilol, bid was introduced
and titrated as needed. For cardiovascular disease patients
over 65 years of age, 6.25 mg Carvedilol, bid was intro-
duced and titrated as needed. If patients were already on a
beta blocker they were switched to 6.25 mg Carvedilol, bid.
For non-CVD patients, they were switched to, or pre-
scribed, 10 mg Nortriptyline, QD, dinner.
Patients who chose against pharmaceutical therapy
were offered an alternative therapy program that included
intensive cardiovascular exercise. For the first six weeks,
only zero-impact, pure cardiac workouts (e.g., swimming,
elliptical machines, long gentle walks, rowing, simulated
cross-country skiing, or elliptical exercise machines) were
recommended. Patients were advised against running or
jogging, weight-lifting, and most team, or contact, sports
to avoid any tissue damage that would stimulate P-activity.
The chosen exercise duration was targeted for 40 minutes
per day for 5 or 6 days per week for the first six weeks.
While the program was intensive, the actual exercise
should be mild. Reaching target heart rate, especially
within the first 20 minutes, was not recommended. Skipping
a week, however, started the 6 weeks over again. Then for
the remainder of the six-month program, the exercise
may be decreased to 3 or 4 days per week, maintaining 40
minutes per event. After six-month and a normalization of
PE, activities that might damage tissue may be returned.
This retrospective study had institutional approval. The
results were analyzed and statistics were computed using
SPSS v14.0.
Results
According to current American Heart Association guide-
lines,22 our study patients ranging in age from 60 to 90 years
had mild hypertension (average BP Z 142/66 mmHg). Pa-
tients who are younger than 60 had normal average BPTable 1 Patient cohort demographics and average resting resp
Ave # F (%) Age Ht (cm) Wt (kg)
<20 358 54.19 15.2 163.5 60.0
20 < 30 601 68.89 24.8 168.1 73.0
30 < 40 1448 62.36 32.2 168.5 78.4
40 < 50 1732 58.20 44.8 168.7 82.8
50 < 60 2175 54.99 54.6 168.3 84.4
60 < 70 2549 54.37 64.8 167.2 82.2
70 < 80 2598 56.97 74.3 166.1 77.2
80 < 90 1352 55.84 83.3 165.6 71.0
>89 154 57.14 92.0 163.3 64.4
Total 12967 57.25 57.7 167.3 78.8(124/77 mmHg). The gender mix within the population
favored females, with the largest percentage of females
presenting in their 20s (Table 1). On average the population
was overweight according to body mass index standards,
but not obese. The patients’ average, mean, resting HR and
BP were 72.9 bpm (12.6 bpm), and 132/72 mmHg (14/
10 mmHg), respectively. The average, resting, mean HR
declined linearly with age from 81 bpm for the youngest
patients to 68 bpm for the oldest. The patients’ average,
resting, systolic BP increased linearly with age from
110 mmHg for the youngest patients to 143 mmHg for the
oldest. Diastolic BP peaked in the fifth decade (40e49 years
old) of life rising linearly from approximately 66 mmHg in
the youngest patients to a peak of approximately 77 mmHg
and then declining linearly to approximately 62 mmHg in
the oldest patients. The cohort’s average resting P&S levels
started well within the normal range and declined steadily
with age.
On average patients began demonstrating advanced
autonomic dysfunction (P or S levels < 0.5 bpm2; indicating
increased morbidity risk) in the sixth decade of life (50e59
years of age). While the average, resting P-activity of the
cohort remained out of the range of cardiovascular auto-
nomic neuropathy (CAN, defined as resting P-
activity < 0.1 bpm,2 indicating increased mortality risk),
the occurrence of CAN was nearly 10% in the sixth decade
(Table 1), rising steadily to 28% by the last decade. Their
Sympathovagal Balance (SBZ 2.1, normal: 0.4 < SB < 3.0)
was normal overall. However, while within normal limits,
the older patients (>65) were considered to demonstrate
high normal SB if their SB > 1.0. The preferred SB for
geriatric patients was a low normal SB (0.4 < SB < 1.0),
indicating more resting P-activity. This was known to be
cardio-protective,23 and associated with reduced morbidity
and mortality risk. All of these average resting responses
were not unexpected, and were mimicked by the subpop-
ulation demonstrating PE during either Valsalva or stand
challenges (P Z 0.0407). On average these patients
appeared normal, at rest. Yet they reported symptoms.
The cohort’s Valsalva and stand responses are presented
in Table 2. On average the Valsalva P&S responses were
within normal limits. However, 22.3% of the cohort
demonstrated SE with Valsalva, with the majority of these
patients presenting with PE after the third decade (afteronses by decade.
Rest
HR BP S P SB CAN (%)
80.8 110/66 6.5 9.1 1.6 0
79.8 116/71 4.9 6.0 1.8 0
78.8 120/74 3.7 4.4 1.8 1
76.5 125/77 2.5 2.4 2.2 3
74.1 130/76 1.7 1.3 2.2 8
71.1 137/72 1.0 0.9 2.5 12
68.3 140/68 0.6 0.5 2.0 16
68.0 142/64 0.4 0.4 2.3 22
68.6 143/62 0.4 0.4 1.6 28
72.9 132/72 1.8 1.9 2.1 10
Table 2 Average patient Valsalva and head-up postural change (stand) responses by decade.
Valsalva Stand
Ave HR BP S P #SE #PE HR BP S P #SW
<20 84.7 112/67 63.8 16.9 5 72 96.2 113/68 11.1 11.7 99
20 < 30 82.0 121/73 64.5 13.7 39 161 90.9 117/74 7.2 9.1 216
30 < 40 81.2 125/76 63.6 13.2 162 536 88.7 121/77 5.9 7.3 478
40 < 50 79.4 130/79 49.6 9.8 191 700 84.9 126/79 3.2 3.7 697
50 < 60 77.1 133/79 33.7 8.4 2114 777 81.3 132/78 2.7 2.3 991
60 < 70 73.8 135/75 20.7 7.9 148 797 76.9 140/74 2.6 1.9 1187
70 < 80 70.9 138/71 13.9 5.2 118 719 73.8 143/70 1.7 2.0 1190
80 < 90 70.3 137/68 7.6 3.9 92 422 73.0 145/67 2.4 2.9 589
>89 70.0 134/62 5.8 5.9 16 55 74.1 143/62 2.2 2.2 61
Total 75.7 132/74 32.2 8.4 2885 4239 80.2 134/74 3.3 3.6 5508
Dynamic parasympathetic excess 55their 20s). PE in response to Valsalva was demonstrated in
significant numbers prior to the third decade. On average
the cohort’s BP response was similar to their resting re-
sponses. The BP response to Valsalva after the sixth decade
(compare Table 2 & Table 1) was an average decrease as
compared with rest.
On average the S-response to stand was within normal
limits. However, a significant amount of sympathetic
withdrawal (SW, the autonomic basis for orthostatic
dysfunction) was demonstrated throughout (Table 2). A
significant amount of stand PE was also demonstrated
throughout (Table 3). SE with stand (an autonomic condi-
tion associated with syncope) was demonstrated at a low
rate within this cohort.
Patients that demonstrated difficult to control BP,
difficult to control blood glucose (as measured by A1c level)
and difficult to control hormone level (as measured by
blood panels for Thyroid Estrogen, or growth hormone)
demonstrated these symptoms at more approximately
three times the rate of non-PE patients (Table 3: 2242/
697, 3115/1121, and 1745/594, respectively). Patients
that demonstrate cardiovascular diseases demonstrated
PE at approximately the same rate as those without PE
(974/869). Patients that demonstrated sleep difficulties
demonstrated PE about a third again as much as non-PE
patients (605/465). Overall, the total prevalence of PE
within this cohort was nearly 60%, with women demon-
strating PE on average about 16% more often than men
(Table 3). This ratio was less in the younger patients, and
was inverted in the second decade.
Of the cohort, 8729 patients (67.3%, 57.9% of them
Female) demonstrated PE during either or both Valsalva or
stand. No clinical difference has been identified between
Valsalva PE or stand PE. Patients that demonstrated PE, on
average demonstrated a higher BP response to Valsalva
than the non-PE patients (P Z 0.0323). As a result, the
older PE patients had a lower prevalence of baroreceptor
reflex dysfunction than the older, non-PE patients. How-
ever, the differences become insignificant when the PE
was relieved (P Z 0.5102). Stand BP changes were not
effected by PE (P Z 0.1497). They were affected by S-
changes: SE was associated with excessive BP responses to
stand (>30 mmHg increase, P Z 0.0182) and SW was
associated with a decrease in BP upon standing (<1 mmHg
increase, P Z 0.0146). PE with stand SE identifies risk of
Vasovagal Syncope.Of this cohort, 44.0% were diagnosed with hypertension.
Within this subpopulation 39.3% (Table 3) demonstrated PE
as compared with 12.2% of the non-PE subpopulation
demonstrating difficult to control BP. Patients diagnosed
with diabetes mellitus, either type 1 or type 2, comprised
64.0% of the cohort: 37.5% were also diagnosed with diffi-
cult to control blood glucose and demonstrated PE as
compared with 13.5% of the non-PE subpopulation. In-
dividuals diagnosed with hormone disorders comprised
33.6% of the cohort: 40.1% were also diagnosed with diffi-
cult to control hormone level and demonstrated PE as
compared with 13.6% of the non-PE subpopulation. Of those
also diagnosed with difficult to control hormone level and
demonstrating PE, 8.1% reporting high levels of thyroid
hormone replacement therapy and continuing complaints
of significant, continuing secondary symptoms. Of the fe-
males in the difficult to control hormone level cohort
demonstrating PE, 19.1% reported menstrual or menopausal
abnormalities. Patients diagnosed with CVD comprised
41.0% of the cohort: 18.3% demonstrated PE as compared
with 16.3% of the non-PE subpopulation. Patients diagnosed
with sleep difficulties (difficult falling asleep or frequent
waking at night, even to go to the bathroom more than
once) comprised 19.3% of the cohort: 24.2% demonstrated
PE as compared with 18.6% of the non-PE subpopulation.
Other symptoms associated with the PE patient cohort
include 23.0% diagnosed with evening edema, restless leg
syndrome, varicose veins, or poor peripheral circulation;
14.4% diagnosed with mild cognitive difficulties thinking
and memory, general malaise, chronic fatigue, or ADD/
ADHD; 14.9% diagnosed with psychological symptoms (e.g.,
depression or anxiety or associated syndromes, including
bipolar, and disorders, or mood shifts); 26.3% diagnosed
with frequent headache or migraines; and 26.6% diagnosed
with gastrointestinal upset (e.g., constipation, abdominal
cramps, nausea, irritable bowel, GERD or acid reflux).
Of the cohort, 80.2% made themselves available for
follow-up autonomic testing. The average time between
tests was 143.9 days. Overall, 63.5% of the patients
demonstrated normalization of PE upon follow-up testing
(Table 4). Of the 36.5% who did not demonstrate normali-
zation, 20.2% demonstrated a reduction in PE and were
considered “works in progress.” Of the 83.7% of the cohort
that demonstrated a reduction or a normalization in PE,
81.6% reported a reduction or relief of symptoms. For the
patients with a history of management difficulties, 85.4%
Table 3 Cohort abnormalities during challenge.
Stand Diagnoses (PE/Non-PE) Total
Ave #SE #PE BP* A1c* Hrmon* CVD Sleep #PE %PE %PE,F
<20 21 149 2/0 24/14 69/14 2/1 14/7 221 61.7 59.3
20 < 30 18 161 16/3 48/31 81/31 16/25 27/15 322 53.6 48.4
30 < 40 64 504 135/33 239/73 73/41 83/45 42/22 1040 71.8 52.7
40 < 50 60 448 161/53 276/111 321/105 92/105 40/86 1148 66.3 59.9
50 < 60 75 617 321/102 460/180 460/102 195/180 297/104 1394 64.1 59.9
60 < 70 97 885 572/208 740/295 387/121 219/191 134/107 1682 66.0 60.4
70 < 80 267 1045 617/209 794/292 212/125 212/225 24/83 1764 67.9 59.3
80 < 90 240 615 373/82 477/113 135/50 135/85 22/36 1037 76.7 60.8
>89 35 66 45/9 57/12 8/6 21/12 5/4 121 78.6 60.3
Total 877 4490 2242/697 3115/1121 1745/594 974/869 605/465 8729 67.3 57.9
BP*Z difficult to control BP, A1c*Z difficult to control blood glucose, Hrmon*Z difficult to control hormone levels (thyroid or estrogen).,
CVD Z cardiovascular disease (e.g., heart failure, coronary artery disease, myocardial infarction).
Table 4 Longitudinal study analysis.
() OC (%) (þ) OC (%) WIP (%) DDP (bpm2) DDBP (mmHg)
Overall
Total 30.77 63.46 20.19 6.07 5.51
() OC NA NA NA 6.13 5.67
(þ)OC NA NA NA 8.81 5.48
Carvedilol
Total 8.65 23.08 3.85 1.03 6.42
() OC NA NA NA 20.99 7.00
(þ)OC NA NA NA 4.96 6.32
Nortriptyline
Total 14.42 22.12 5.77 12.99 6.34
() OC NA NA NA 0.59 5.89
(þ)OC NA NA NA 17.21 6.48
Alternative
Total 6.73 19.23 2.88 2.48 3.22
() OC NA NA NA 0.005 3.5
(þ)OC NA NA NA 2.91 3.17
() Z negative, (þ) Z positive, OC Z Outcomes, WIP Z work in progress, DD Z change in a response.
56 D.L. Bellin et al.demonstrated more stable BP, blood glucose, or hormone
level control. The CVD cohort patients demonstrated a
48.6% reduction in co-morbidities, including: GI upset,
sleep difficulties, depression, and dizziness. Of the sleep
cohort patients, 54.8% demonstrated a normalization of
sleep difficulties and co-morbidities, including GI upset,
depression, and fatigue.
Considering the individual treatment modalities (Carve-
dilol, Nortriptyline, and Alternative), the total 63.5% posi-
tive outcomes rate was nearly equally distributed amongst
the three modalities (Table 4). The Nortriptyline group
within the cohort had the highest negative outcome rate
(14.42%), approximately twice that of the other two. The
alternative treatment modality had the lowest negative
outcome rate (6.73%).
Overall, the average change in the PE was an improve-
ment, a change of 6.07 bpm2 (a decrease, Table 4). With
the whole cohort, those with poor outcomes over the nearly
five months of therapy demonstrated an average change inPE of þ6.13 bpm2 (an increase), and those with improved
outcomes demonstrated an average change in the PE of
8.81 bpm2 (a decrease). The average change in PE with
Carvedilol was an improvement, a change of 1.03 bpm2 (a
decrease). Those with poor outcomes in response to Car-
vedilol demonstrated an average change in PE of
þ20.99 bpm2 (an increase), and those with improved out-
comes demonstrated an average change in PE of
4.96 bpm2 (a decrease). The average change in PE with
Nortriptyline demonstrated the greatest improvement: an
overall change of 12.99 bpm2 (a decrease). Those with
poor outcomes in response to Carvedilol demonstrated an
average change in PE of þ0.59 bpm2 (an increase), and
those with improved outcomes demonstrated an average
change in PE of 17.21 bpm2 (a decrease). Alternative
therapy demonstrated the greatest success, in that it has
the lowest negative outcome increased in PE (0.005 bpm2).
The average change in PE with alternative therapy was an
overall change of 2.48 bpm2 (a decrease). Those with
Dynamic parasympathetic excess 57improved outcomes demonstrated an average change in PE
of 2.91 bpm2 (a decrease). There was very little change in
the BP responses regardless of the treatment modality.Discussion
PE (whether Valsalva or stand) is associated with: difficult
to control BP, blood glucose, or hormone level, difficult to
describe pain syndromes, difficult to manage weight-loss,
unexplained arrhythmia (palpitations) or seizure, and
symptoms of depression or anxiety, attention deficit dis-
orders, fatigue, exercise intolerance, sex dysfunction,
sleep or GI disturbance, dizziness, or frequent headache or
migraine.
Therapy, in part, works to retrain the ANS to react
normally to stresses, resulting in a net increase in S-activity
following a net decrease in P-activity. Therapy works
inhibiting P-activity while permitting moderate S-activity,
thereby retraining P-activity to not react to stressful ac-
tivities, making for a more normal response.
In general and for treatment, when SE is demonstrated
with PE (whether demonstrated during Valsalva or stand),
consider the SE secondary. Treat the PE as the primary
autonomic dysfunction. Often, upon doing so, SE is reduced
or relieved within about three months and the SE-related
symptoms are reduced or relieved within another three
months. Valsalva SE is known to be secondary to Valsalva
PE, and is associated with depression with hypertension,
depression with anxiety, and dizziness with hypertension
patients, including attention deficit, Fibromyalgia, Fatigue,
and PTSD patients. Stand SE with stand PE (Table 3) is
associated with (pre-clinical) Vasovagal Syncope. The rate
of stand SE (0.07%) is comparable to the rate of Syncope
within this cohort.
Stand PE is known to inflate stand S-response (comparing
Table 2 & Table 1). With the high rate of stand PE, the rate
of SW (Table 2) may be artificially low and may explain the
weak average BP response to stand (average change in BP
(DBP) Z 2/2 mmHg). The expected DBP is at least 10%,
therefore, the expected average DBP is at least an increase
of 13/7 mmHg.
PE before the third decade (20se30s, Table 3), may
help to explain the high rate of attention deficit disorders
and depression in younger patients. These patients often
complain of GI upset and difficulties falling asleep or
staying asleep, with fatigue during daylight hours. With
PE, this may not be volitional. The PE seems to invert their
circadian cycle. Therefore, during the day and in order to
maintain proper brain perfusion, these patients need
extra stimulation to overcome the P-tendencies. This
seems especially true for males. The gender ratio is
nearest to 50% in the first three daces of life, and the only
decade in which the gender ratio is in favor of males is in
the third decade.
The decline in the PE rate in the third decade (Table 3,
from 61.7% to 53.6%) seems to be due to the decline in the
rate of PE in females (from 59.3% to 48.4%). The decline in
the rate of PE in females may be a result of first pregnan-
cies helping to “re-set” P&S imbalances resulting from
hormone difficulties (including the dynamic imbalances
with challenge). However, multiple pregnancies often re-establish PE and is associated with peri-menopausal and
menopausal symptoms.
PE with Valsalva with an abnormal BP response to Val-
salva is associated with baroreceptor reflex dysfunction.
The decrease in average BP in cohort patients in response
to Valsalva over the last two decades of life is associated
with the increase in baroreceptor reflex dysfunction during
that time.
The lack of significant change in the BP responses
(compare Table 2 to Table 1) is due, in part, to two
mechanisms. One, it often takes a while longer to effect a
BP change through changing PE. Two, PE masks SW, which
underlies orthostatic dysfunction. Patient’s BP is often
found to be higher with orthostasis as a compensatory
mechanism, guarding against dizziness and lightheaded-
ness. Regarding secondary SE, it is known that the sympa-
thetics control baroreceptor reflex which controls BP. PE
forces a secondary SE. When the PE is relieved, then the SE
follows, then baroreceptor reflex normalizes, then BP
normalizes. Since it may take up to 18 months for PE
normalization, the 15 months of this study may not have
been enough time to realize BP normalization. Normalizing
PE also unmasks SW. With normalization of SW, BP also,
naturally, reduces. Again, the 15 months of this study may
not have been enough time to realize BP normalization.
Specific Chiropractic Adjustments (SCA), better known
in the literature as Chiropractic Manipulative Therapy
(CMT), are known to effect P&S activity. Evidence suggests
that cervical and sacral adjustments seem to affect P-ac-
tivity and elicit P-responses; whereas, thoracic and lumbar
adjustments seem to effect S-activity and elicit S-responses
or both. Furthermore, it appears that these responses may
demonstrate the relationship of autonomic responses in
association to the particular segment(s) adjusted.24 There
is evidence suggesting that muscle spindles in cervical
paraspinal muscles may in fact be capable of eliciting
somato-autonomic reflexes.25 Additionally, conscious
human studies demonstrate that innocuous somatic stimu-
lation of the neck influences cardiovascular function.26
Many characteristics of the P&S nervous systems corre-
late with characteristics of Yin and Yang, respectively.
Clinical application of these P&S characteristics is the
essence of TCM philosophy of balance in practice. These
characteristics indicate a correlation between P-activity
and Yin, and S-activity and Yang; since it appears we can
quantify P&S responses for individual patients it should
follow that we can quantify Yin and Yang. Quantifying P&S
and Yin and Yang subserves both emergency-rescue medi-
cine (after one is sick, e.g., diabetes, hypertension, heart
disease, sleep apnea, depression, dizziness, and pain) and
proactive-preventative healthcare (before one is sick). It
provides more information about an individual patient’s
condition after symptoms present. Therefore the TCM
practices of Acupuncture, Spinal Manipulation, Tuina, and
TCM medicine benefit patients by balancing Yin and Yang
system, as one example.
The P-nervous system is protective (cardiac and other-
wise). PE may have a genetic predisposition. PE seems to
present after long periods of low-level stress (i.e, chronic
disease) or after intense stress (including pregnancy,
trauma, surgery, exposure). PE seems to be part of the
body’s response to stress. For patients who have difficulty
58 D.L. Bellin et al.losing weight and keeping weight off, stressful exercise
may lead to their P-nervous systems preventing the meta-
bolism of fat to protect against future stresses. These pa-
tients are often exercise intolerant, especially if they are
dieting, because they only have the sugars in their blood to
exercise with.
The goal of exercise therapy in PE patients is to raise HR,
BP and cardiac output, and sweat (stimulate, gently, S-
activity) without causing any tissue damage or other means
of stimulating the P-nervous system. “Target heart rate”
should not be a goal. Repair of tissue damage, including
micro-tears in joint cartilage, may stimulate P-activity to
mediate healing. Patients with PE react to stress by
increasing P-activity to protect the body. The result is to
over-stimulate S-activity. Gentle, stimulation of S-activity
without inducing P-activity retrains the ANS to react nor-
mally to stresses.
PE appears to destabilize patients’ responses to disease
and therapy. PE appears to mask SW upon standing: 26.7%
of patients with dizziness and a drop in BP or more than
5 mmHg systolic demonstrated PE with no SW until PE was
treated. It is associated with 83.2% of the patients diag-
nosed with Vasovagal Syncope. In pain patients, PE is
associated with 77.4% of pain patients diagnosed with
chronic regional pain syndrome and 86.2% of patients
diagnosed with fibromyalgia.
After treating for PE, more than half of the patients re-
ported increased dizziness upon standing, especially in pa-
tients with CVD. As a result, when CVD patients with PE are
prescribed Carvedilol, they are also given low-doseMidodrine
(2.5 mg QD, dinner), history dependent. We have observed
that correcting for this dynamic autonomic imbalance may
reduce the severity of the primary disease or disorder, and, in
some cases, eliminate symptoms all together.Conclusion
The current working hypothesis is that challengedValsalva
or postural changedPE is independent of the clinical state
of the patient and, depending on history, may be treated
independent of, or concurrent with, the primary disease.
This dynamic autonomic imbalance has been found to have
clinical relevance, in that when the imbalance is corrected,
patients report feeling better and their clinical status be-
comes more stable or even relieved. Longitudinal studies
have shown that relieving this PE may reduce or relieve
other autonomic dysfunctions, also helping to stabilize
underlying disease (e.g., hypertension, diabetes, cardio-
myopathy, menopause symptoms, and hypothyroidism).
PE may explain why many patients present with vague
diffuse symptoms, but demonstrate normal responses (at
rest) according to most tests, including echocardiogram and
EKG. In most cases PE patients have been weaned from
pharmaceutical therapy within 18 months. Our clinical ob-
servations show that patients’ ANS may be retrained to
function at a different “set point” and left to carry on in-
dependent of clinical support once PE is relieved. In some
cases where end-organ effects from either the primary
disease or from PE have not yet presented, such as thick-
ening of heart muscle due to hypertension, patients may be
able to stop life-long therapy once the PE is resolved.Many common chronic conditions such as hormone
imbalance (including diabetes) or CVD may cause P&S
imbalance. Severe acute conditions may also precipitate
PE, including trauma, injury, infection, surgery, cancer,
and pregnancy. When patients present with varied and
multiple symptoms, establishing PE may help clarify the
diagnosis and provide direction for therapeutic options. PE
is often the primary autonomic disorder and the S-abnor-
malities are secondary to the PE. Often a single agent or a
combination of agents may address such autonomic disor-
ders and treat PE. Correcting the underlying PE among
patients with other acute or chronic disease, facilitates
more aggressive and targeted therapy. Once PE is cor-
rected, clinicians often have improved success in manage-
ment of the primary disease(s) and patients may become
less symptomatic and have improved outcomes and quality
of life.Conflicts of interest
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